Tiziana Life Sci PLC - Proposed Admission to the Official List
("Tiziana" or the "Company")
Early notification of proposed admission to the Official List and cancellation of trading on AIM
The Company Directors believe that a standard listing in conjunction with its NASDAQ dual listing will support the long-term strategy of the Company by providing the Company with a more appropriate platform for its growth as an international company. In addition, the Company Directors believe that Admission will raise the Company's global profile, increase its trading liquidity and provide the Company with a greater range of potential investors for its ordinary shares.
Admission will be through an introduction of the existing Ordinary Shares. The Company will not be issuing new shares in conjunction with the proposed Admission or the publication of the related prospectus, and has no current intention to raise capital through the issue of new shares in the
Pursuant to Rule 41 of the AIM Rules for Companies, the Company will, in due course, give formal notice of the intended cancellation of trading of its Ordinary Shares on the AIM market of the
It is expected that the Company will publish its prospectus in connection with Admission in late Q3 or early Q4 2020 and that the Ordinary Shares will be admitted to the Official List, commence trading on the Main Market and simultaneously trading will be cancelled on AIM (and at least 20 business days after the formal announcement under Rule 41 of the AIM Rules for Companies), subject to the receipt of the necessary approvals from the
The Company's shares will continue to be registered with their existing ISIN number GB00BKWNZY55. The Company's ticker symbol in the
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the release of this information is Keeren Shah, Finance Director of Tiziana.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further enquiries:
| || |
+44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated adviser)
+44 (0)20 7213 0880
+44 (0)20 3981 4173
This information is provided by RNS, the news service of the
Quick facts: Tiziana Life Sciences PLC
Market Cap: £269.54 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE